- China has been a major Covid vaccine supplier to much of the developing world, but the U.S. is now catching up, said Huang Yanzhong, senior fellow for global health at the Council on Foreign Relations.
- The White House last week laid out plans to donate millions of Covid vaccine doses overseas and reports have emerged that President Joe Biden wants to do more.
- U.S.-China relations had been off to a rocky start under the Biden administration, with both sides clashing over several issues including the origins of the coronavirus.
U.S.-China competition may be heating up on another front: Covid-19 vaccine diplomacy.
China has been a major Covid vaccine supplier to much of the developing world, an effort that some experts said could bolster Beijing's global influence and deepen its ties with other nations.
But a health governance and policy expert told CNBC on Thursday that the U.S. is now catching up, with the White House laying out plans to donate millions of Covid vaccine doses overseas and it appears President Joe Biden intends to do more.
"We're going to see that China is going to face a more formidable competitor," Yanzhong Huang, senior fellow for global health at the Council on Foreign Relations, told CNBC's "Squawk Box Asia."
In the last few months, China has been "almost the only primary player" sending Covid vaccines to other countries, said Huang, who is also a professor at Seton Hall University's School of Diplomacy and International Relations.
That's especially so when India halted vaccine exports to prioritize its domestic needs and Russia's supply overseas remains very limited, he explained.
Several reports have pointed to the U.S. ramping up its effort to share Covid vaccines globally.
Biden is reportedly set to announce in a speech at the G-7 summit on Thursday that the U.S. will buy 500 million more doses of the Pfizer-BioNTech vaccine to share with COVAX, a global vaccine-sharing initiative.
Publicly available clinical trial data so far show that the Pfizer-BioNTech and Moderna shots have higher efficacy rates — of over 90% — at preventing Covid infections compared with those developed by Chinese firms.
Questions have risen over the efficacy of Chinese vaccines, with countries including Bahrain and Chile reporting an increase in cases despite vaccinating their populations quicker than many countries.
The World Health Organization said earlier this month that studies showed the vaccine by Chinese drugmaker Sinovac Biotech prevented symptomatic disease in 51% of those vaccinated and prevented severe Covid-19 and hospitalization in 100% of the studied population.
Origins of Covid-19
Relations between the U.S. and China had been off to a rocky start under the Biden administration. The two sides have clashed on several issues, including the origins of the coronavirus, which was first detected in the Chinese city of Wuhan.
Biden last month said he's ordered a closer intelligence review of the pandemic's origins, including whether the virus had escaped from a Chinese laboratory. In response, China accused the U.S. of a political "blame game."
Huang said the issue of Covid-19's origins has become so politicized that it's likely to stoke further U.S.-China tensions if additional evidence emerges to support the possibility that Covid-19 had originated from a laboratory incident.
Without China's cooperation, such "smoking gun" evidence may not be found, said Huang. Yet, in the West, the theory that the virus came from a lab has become an increasingly "credible, if not mainstream, explanation" of the pandemic's origin, he said.